Andrographolide inhibits tumor angiogenesis via blocking VEGFA/VEGFR2-MAPKs signaling cascade

Chemico-Biological Interactions

Volumn 218, Issue , 2014, Pages 99-106

  Shen, Kaikai ^a   Ji, Lili ^a   Lu, Bin ^a   Xu, Chong ^a   Gong, Chenyuan ^a   Morahan, Grant ^b   Wang, Zhengtao ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Andrographolide; Mitogen activated protein kinases; Tumor angiogenesis; Vascular endothelial growth factor A; Vascular endothelial growth factor receptor 2

Indexed keywords

ANDROGRAPHOLIDE; MITOGEN ACTIVATED PROTEIN KINASE; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG INHIBITION; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANDROGRAPHOLIDE; MITOGEN-ACTIVATED PROTEIN KINASES; TUMOR ANGIOGENESIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 2;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL SURVIVAL; CELLS, CULTURED; DITERPENES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, ANIMAL; MOLECULAR STRUCTURE; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84901664648     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2014.04.020     Document Type: Article

References (39)

1. D. Hanahan, and J. Folkman Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 86 1996 353 364 (Pubitemid 26272076)
2. J. Folkman, and Y. Shing Angiogenesis J. Biol. Chem. 267 1992 10931 10934
3. J. Waltenberger, L. Claesson-Welsh, A. Siegbahn, M. Shibuya, and C.H. Heldin Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor J. Biol. Chem. 269 1994 26988 26995 (Pubitemid 24332901)
4. H. Gille, J. Kowalski, B. Li, J. Moffat, T.F. Zioncheck, N. Pelletier, and N. Ferrara Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants J. Biol. Chem. 276 2001 3222 3230
5. J. Waltenberger, W.L. Claesson-Welsh, A. Siegbahn, M. Shibuya, and C.H. Heldin Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor J. Biol. Chem. 269 1994 26988 26995 (Pubitemid 24332901)
6. X. Pang, T. Yi, Z. Yi, S.G. Cho, W. Qu, D. Pinkaew, K. Fujise, and M. Liu Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting Rho GTPases and extracellular signal-regulated kinase signaling pathways Cancer Res. 69 2009 518 525
7. Y. Asami, H. Kakeya, Y. Komi, S. Kojima, K. Nishikawa, K. Beebe, L. Neckers, and H. Osada Azaspirene, a fungal product, inhibits angiogenesis by blocking Raf-1 activation Cancer Sci. 99 2008 1853 1858
8. X. Yu, J. Zhu, M. Mi, W. Chen, Q. Pan, and M. Wei Anti-angiogenic genistein inhibits VEGF-induced endothelial cell activation by decreasing PTK activity and MAPK activation Med. Oncol. 29 2012 349 357
9. N. Ferrara, H.P. Gerber, and J. LeCouter The biology of VEGF and its receptors Nat. Med. 9 2003 669 676 (Pubitemid 36749215)
10. O. Stoeltzing, and L.M. Ellis Regulators of vascular endothelial growth factor expression in cancer Cancer Treat. Res. 119 2004 33 58
11. E. Cabebe, and H. Wakelee Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors Curr. Treat. Options Oncol. 8 2007 15 27
12. A.K. Olsson, A. Dimberg, J. Kreuger, and L. Claesson-Welsh VEGF receptor signaling-in control of vascular function Nat. Rev. Mol. Cell Biol. 7 2006 359 371
13. K.K. Shen, T.Y. Liu, C. Xu, L.L. Ji, and Z.T. Wang Andrographolide inhibits hepatoma cells growth and affects the expression of cell cycle related proteins Yao Xue Xue Bao 44 2009 973 979
14. K. Sheeja, C. Guruvayoorappan, and G. Kuttan Antiangiogenic activity of Andrographis paniculata extract and andrographolide Int. Immunopharmacol. 7 2007 211 221 (Pubitemid 46037562)
15. P. Pratheeshkumar, and G. Kuttan Andrographolide inhibits human umbilical vein endothelial cell invasion and migration by regulating MMP-2 and MMP-9 during angiogenesis J. Environ. Pathol. Toxicol. Oncol. 30 2011 33 41
16. V. Marin, G. Kaplanski, S. Gres, C. Farnarier, and P. Bongrand Endothelial cell culture: protocol to obtain and cultivate human umbilical endothelial cells J. Immunol. Methods 254 2001 183 190 (Pubitemid 32530758)
17. G.A. McMahon, E. Petitclerc, S. Stefansson, E. Smith, M.K. Wong, R.J. Westrick, D. Ginsburg, P.C. Brooks, and D.A. Lawrence Plasminogen activator inhibit-1 regulates tumor growth and angiogenesis J. Biol. Chem. 276 2001 33964 33968
18. A. Card, C. Caldwell, H. Min, B. Lokchander, H.L. Xi, S. Sciabola, A.V. Kamath, S.L. Clugston, W.R. Tschantz, L.Y. Wang, and D.J. Moshinsky High-throughput biochemical kinase selectivity assays: panel development and screening applications J. Biomol. Screen. 14 2009 31 42
19. N. Awasthi, M.A. Schwarz, V. Verma, C. Cappiello, and R.E. Schwarz Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling Lab. Invest. 89 2009 38 46
20. G. Bergers, and L.E. Benjamin Tumorigenesis and the angiogenic switch Nat. Rev. Cancer 3 2003 401 410 (Pubitemid 37328844)
21. J. Folkman Tumor angiogenesis: therapeutic implications N. Engl. J. Med. 285 1971 1182 1186
22. T. Yi, Z. Yi, S.G. Cho, J. Luo, M.K. Pandey, B.B. Aggarwal, and M. Liu Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling Cancer Res. 68 2008 1843 1850 (Pubitemid 351416570)
23. S. Shankar, Q. Chen, and R.K. Srivastava Inhibition of PI3K/AKT and MEK/ERK pathways act synergistically to enhance antiangiogenic effects of EGCG through activation of FOXO transcription factor J. Mol. Signaling 20 2008 3 7
24. M. Kudo Molecular targeted therapy for hepatocellular carcinoma: bench to beside Dig. Dis. 29 2011 273 277
25. L.L. Ji, K.K. Shen, J. Liu, Y. Chen, T.Y. Liu, and Z.T. Wang Intracellular glutathione regulates Andrographolide-induced cytotoxicity on hepatoma Hep3B cells Redox Rep. 14 2009 176 184
26. L.L. Ji, T.Y. Liu, J. Liu, Y. Chen, and Z.T. Wang Andrographolide inhibits human hepatoma-derived Hep3B cell growth through the activation of c-Jun N-terminal kinase Planta Med. 73 2007 1397 1401 (Pubitemid 350084459)
27. L. Ji, K. Shen, P. Jiang, G. Morahan, and Z.T. Wang Critical roles of cellular glutathione homeostasis and jnk activation in andrographolide-mediated apoptotic cell death in human hepatoma cells Mol. Carcinog. 50 2011 580 591
28. A.X. Zhu, D.G. Duda, D.V. Sahani, and R.K. Jain HCC and angiogenesis: possible targets and future directions Nat. Rev. Clin. Oncol. 8 2011 292 301
29. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934 (Pubitemid 35425239)
30. R. Seger, and E.G. Krebs The MAPK signaling cascade FASEB J. 9 1995 726 735
31. G. Mordret MAP kinase kinase: a node connecting multiple pathways Biol. Cell 79 1993 193 207 (Pubitemid 24110555)
32. S. Rousseau, F. Houle, J. Landry, and J. Huot P38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells Oncogene 15 1997 2169 2177 (Pubitemid 27493906)
33. S. Miura, Y. Matsuo, and K. Saku Jun N-terminal kinase inhibitor blocks angiogenesis by blocking VEGF secretion and an MMP pathway J. Atheroscler. Thromb. 15 2008 69 74
34. K.T. Lin, J.C. Lien, C.H. Chung, S.C. Kuo, and T.F. Huang A novel compound, NP-184, inhibits the vascular endothelial growth factor induced angiogenesis Eur. J. Pharmacol. 630 2010 53 60
35. L. Morbidelli, A. Pyriochou, S. Filippi, I. Vasileiadis, C. Roussos, Z. Zhou, H. Loutrari, J. Waltenberger, A. Stossel, A. Giannis, M. Ziche, and A. Papapetropoulos The soluble guanylyl cyclase inhibitor NS-2028 reduces vascular endothelial growth factor-induced angiogenesis and permeability Am. J. Physiol. Regul. Integr. Comp. Physiol. 298 2010 R824 R832
36. A. Pyriochou, D. Beis, V. Koika, C. Potytarchou, E. Papadimitriou, Z. Zhou, and A. Papapetropoulos Soluble guanylyl cyclase activation promotes angiogenesis J. Pharmacol. Exp. Ther. 319 2006 663 671
37. N. Ibrahim, Y. Yu, W.R. Walsh, and J.L. Yang Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies Oncol. Rep. 27 2012 1301 1311
38. S.R. Brave, R. Odedra, N.H. James, N.R. Smith, G.B. Marshall, K.L. Acheson, D. Baker, Z. Howard, L. Jackson, K. Ratcliffe, A. Wainwright, S.C. Lovick, D.M. Hickinson, R.W. Wilkinson, S.T. Barry, G. Speake, and A.J. Ryan Vandetanib inhibits both VEGFR-2 and EGFR signaling at clinically relevant drug levels in preclinical models of human cancer Int. J. Oncol. 39 2011 271 278
39. S.J. Shin, M. Jung, H.C. Jeung, H.R. Kim, S.Y. Rha, J.K. Roh, H.C. Chung, and J.B. Ahn A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDGF) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy Invest. New Drugs 30 2011 1501 1510